Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension
| Status: | Completed |
|---|---|
| Conditions: | High Blood Pressure (Hypertension) |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 50 |
| Updated: | 5/5/2014 |
| Start Date: | July 2010 |
| End Date: | June 2011 |
| Contact: | Jason Davis, MD |
| Email: | jtd002@ucsd.edu |
| Phone: | 858-534-0619 |
Effects of the Novel Beta-adrenergic Antagonist Nebivolol (Bystolic) on Prehypertensive Subjects at Genetic Risk of Hypertension: Implications for Inflammation, Endothelial Dysfunction, and Oxidative Stress.
The investigators aim to evaluate subjects at high risk of future development of
hypertension, those with a family history of hypertension and/or that already have high
normal(SBP 120-139 mmHg or DBP 80-89 mmHg) blood pressure. The investigators plan to
investigate whether these subjects have the same markers (such as microscopic protein in the
urine or C-reactive protein in the blood) in the blood and urine that people with high blood
pressure have, and whether they are improved before and after taking the beta-blocker
nebivolol.
hypertension, those with a family history of hypertension and/or that already have high
normal(SBP 120-139 mmHg or DBP 80-89 mmHg) blood pressure. The investigators plan to
investigate whether these subjects have the same markers (such as microscopic protein in the
urine or C-reactive protein in the blood) in the blood and urine that people with high blood
pressure have, and whether they are improved before and after taking the beta-blocker
nebivolol.
Inclusion Criteria:
- • Prehypertensive male and female subjects with SBP =120-139 or DBP =80-89 with at
least one known family member (must be diagnosed prior to the age of 60) with
essential hypertension (confirmation may be sought).
- All ethnicities
- Non-smokers and non-drug abusers, no current smoking or illicit drug use in the
prior 3 months.
- Aged 18-40 years
- No known serious medical conditions requiring close monitoring from physicians-
such as liver impairment, chronic kidney disease, or diabetes mellitus
- Subjects will need to remain in the San Diego area for the duration of the study
(10 weeks) and be accessible by telephone or email.
- Female subjects must be willing to use a birth control method, such as
abstinence, birth control pills, diaphragm, condom, or intrauterine device to
prevent pregnancy during the study.
Exclusion Criteria:
- Subjects with SBP >140 or SBP<120 or DBP >90 and DBP<80
- We will exclude subjects whose family members have known secondary etiologies for
hypertension such as hyperaldosteronism or Cushing's Disease.
- Subjects cannot have a chronic medical condition that is actively treated by a
physician, such as liver impairment, diabetes, or kidney disease
- History of bronchial asthma or chronic obstructive pulmonary disease
- Subjects cannot be on any anti-hypertensive medications for any reason.
- Subjects may not have previous intolerance, hypersensitivity, or allergy to any beta
blocker therapy or may have contraindications to beta blocker therapy such as asthma,
bradycardia, etc.
- Subjects may not be taking medications which may affect the metabolism of nebivolol,
such as those that inhibit CYP2D6 (such as fluoxetine or cimetidine)
- Nursing women, pregnant women, or those that plan to become pregnant in the study
period will also be excluded. (Pregnancy tests will be performed on all female
subjects at the start of the study)
- Subjects with pulse rate consistently <60 beats per minute or evidence of arrythmias
including atrioventricular block.
- Those that have smoked or used illicit drugs within the past 3 months
- Female subjects that are not willing to use a birth control method, such as
abstinence, birth control pills, diaphragm, condom, or intrauterine device to prevent
pregnancy during the study.
We found this trial at
1
site
The University of California, San Diego UC San Diego is an academic powerhouse and economic...
Click here to add this to my saved trials
